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Abstract
PURPOSE: It was to assess the risk of cardiovascular disease (CVD) in breast cancer survivors (BCS). METHODS: 
This cross-sectional study analyzed 67 BCS, aged 45–65 years, who underwent complete oncological treatment, but 
had not received hormone therapy, tamoxifen or aromatase inhibitors during the previous 6 months. Lipid profile and CVD 
risk were evaluated, the latter using the Framingham and Systematic COronary Risk Evaluation (SCORE) models. The 
agreement between cardiovascular risk models was analyzed by calculating a kappa coefficient and its 95% confidence 
interval (CI). RESULTS: Mean subject age was 53.2±6.0 years, with rates of obesity, hypertension, and dyslipidemia 
of 25, 34 and 90%, respectively. The most frequent lipid abnormalities were high total cholesterol (70%), high LDL-C 
(51%) and high non-HDL-C (48%) concentrations. Based on the Framingham score, 22% of the participants had a high 
risk for coronary artery disease. According to the SCORE model, 100 and 93% of the participants were at low risk 
for fatal CVD in populations at low and high risk, respectively, for CVD. The agreement between the Framingham and 
SCORE risk models was poor (kappa: 0.1; 95%CI 0.01–0.2) for populations at high risk for CVD. CONCLUSIONS: 
These findings indicate the need to include lipid profile and CVD risk assessment in the follow-up of BCS, focusing on 
adequate control of serum lipid concentrations.
Resumo
OBJETIVO: Avaliar o risco de doença cardiovascular (DCV) em mulheres com câncer de mama. MÉTODOS: Foi conduzido 
estudo de corte transversal, com 67 mulheres com câncer de mama, entre 45 e 65 anos, tratamento oncológico 
completo, não usuárias de terapia hormonal, tamoxifeno ou inibidores da aromatase nos últimos 6 meses. Foram 
avaliados o perfil lipídico e o risco de DCV. Para avaliar o risco de DCV, foram utilizados os modelos Framingham e 
Systematic COronary Risk Evaluation (SCORE). Para investigar a concordância entre os modelos de risco cardiovascular, 
foi calculado o coeficiente kappa com seu respectivo intervalo de confiança (IC) de 95%. RESULTADOS: A média 
de idade das participantes foi de 53,2±6,0 anos. A prevalência de obesidade, hipertensão e dislipidemia foi 25, 
34 e 90%, respectivamente. A prevalência de dislipidemia foi 90%. As anormalidades mais comuns do perfil lipídico 
foram: alto colesterol total (70%), alto LDL-C (51%) e alto não HDL-C (48%). Baseado no escore de Framingham, 22% 
das mulheres com câncer de mama apresentaram alto risco de doença arterial coronariana. De acordo com o modelo 
SCORE, 100 e 93% das participantes apresentaram baixo risco de DCV fatal, considerando populações de baixo 
e alto risco de DCV, respectivamente. A concordância entre os modelos de Framingham e SCORE foi ruim (kappa: 
0,1; IC95% 0,01–0,2), considerando populações de alto risco de DCV. CONCLUSÕES: Esses dados indicam a 
necessidade de incluir a avaliação do perfil lipídico e do risco de DCV na rotina de seguimento de mulheres com 
câncer de mama, sendo observadoo adequado controle dos níveis séricos de lipídios.
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Introduction
There are currently millions of women diagnosed with 
breast cancer, who are going through a phase termed the 
menopause transition, in which there is an increased 
susceptibility to cardiovascular events1. Coronary heart 
disease (CHD) and cerebrovascular disease are the main 
cardiovascular diseases. Cardiovascular disease (CVD) is 
the leading cause of death in women worldwide, compet-
ing with breast cancer as the primary cause of death in 
breast cancer survivors (BCS)2.
Dyslipidemia, obesity, age, smoking, sedentary life-
style, hypertension and diabetes mellitus are known risk 
factors for CVD1. Previous studies have identified the high 
prevalence of CVD risk factors in middle-aged women3,4. 
Elevated serum levels of total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C) and triglycerides (TG) 
were described in perimenopausal women5,6. The behavior 
of high-density lipoprotein cholesterol (HDL-C) levels 
in the menopause transition is less clear and reports have 
described that HDL-C concentration is not correlated 
with menopause status6.
At midlife, BCS may present the same risk factors 
for CVD as women without breast cancer. As a result, 
BCS may develop CHD. A higher measurement of TC, 
LDL-C and TG was reported in BCS, when compared to 
non-BCS7,8. Furthermore, a relationship between obesity 
and unfavorable lipid profilehas been demonstrated in 
BCS8,9. Correlations between obesity10-12, higher blood 
pressure and lipid levels11with worse survival rates in BCS 
were observed. The addition of traditional risk factors 
for CVD to chemotherapy13-15, radiotherapy14, targeted 
therapy16 and endocrine therapy17 may increase CVD risk 
in BCS. Use of endocrine therapy may be associated with 
favorable or unfavorable alterations in lipid profile17,18.
CVD risk may be assessed by algorithms or math-
ematical models. Among the cardiovascular risk  assessment 
models, the Framingham Risk Score (FRS)19 and the 
Systematic COronary Risk Evaluation (SCORE)20 are 
highlighted. The FRS, developed in the United States, 
is the most widely used algorithm worldwide19 for cal-
culation of CHD risk19. On the other hand, European 
guidelines recommend the application of the SCORE 
system, developed and validated in European countries20. 
The SCORE system estimates the risk of fatal CVD20. The 
prognostic performance of CVD risk assessment models 
may vary according to the population studied21,22 and the 
clinical condition of the patients23,24.
Therefore, the aim of the present study was to in-
vestigate the prevalence of CVD risk factors, estimate 
cardiovascular risk according to the FRS and SCORE 
model, and evaluate the agreement between these two 
cardiovascular risk estimation models in middle-aged BCS.
Methods
Patients
Participant selection has been previously described 
in detail25. Briefly, the current sample originated from 
the Brazilian Breast Cancer and Menopause (BBCAM) 
study. BBCAM study had a cross-sectional design 
and was conducted to investigate the prevalence of 
menopause symptoms, sexual activity, quality of life, 
bone mineral density and CVD risk in middle-aged 
BCS25.We focused on the cardiovascular risk factors 
found in this study.
Participants of this study were selected among pa-
tients consecutively treated in the Menopause and Breast 
Cancer Outpatient Facilities in the Women’s Hospital, 
located at the Universidade Estadual de Campinas, 
Brazil, between August 2002 and June 2003. During 
outpatient consultation, patients who met the inclusion 
criteria were invited to participate in the study. BCS, aged 
45–65 years, who had not received menopause hormone 
therapy, tamoxifen or aromatase inhibitors in the last 6 
months, and had no history of other malignant tumors 
were included in the study. Women were invited to par-
ticipate regardless of menopause status. One hundred BCS 
were consecutively invited to participate in the study. 
Three patients refused due to lack of time. Twenty-two 
patients were undergoing oncology treatment and eight 
had no record of lipid profile. Sixty-seven BCS comprised 
the present study sample.
Participants provided information on their so-
ciodemographic characteristics, including age, race/
ethnicity, and marital status. Clinical characteristics 
included body mass index (weight in kg/height in 
m2), smoking status, diabetes mellitus, blood pres-
sure levels, time since breast cancer diagnosis, tumor 
stage, chemotherapy, and radiotherapy. Overweight 
and obese patients were defined asthose having a body 
mass index (BMI) between  25.0–29.9 kg/m2 and ≥30 
kg/m2, respectively. Blood pressure was measured after 
rest. Hypertension was defined as a self-reported and/or 
blood pressure measurement ≥140 and/or ≥90 mmHg. 
Diabetes mellitus was defined as a self-reported medi-
cal diagnosis. The study was approved by the internal 
review board of the institution. All women signed an 
informed consent term.
The mean age of the participants was 53.2±6.0 years 
and mean time since breast cancer diagnosis was 67.7±55.0 
months. The mean BMI was 27.8±5.7 kg/m2. Seventy 
percent of the participants reported having one partner, 
73% were white, and 84% were postmenopausal. Seventy-
two per cent of the participants underwent chemotherapy, 
and 72% received radiotherapy. Other characteristics of 
the participants are shown in Table 1.
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Lipid profile
After a 12 hour-fast, blood samples were collected 
for analysis of serum TC, HDL-C and TG levels. Plasma 
levels of TC, HDL-C and TG were measured by an en-
zymatic colorimetric method (Roche Modular system, 
Roche Diagnostics, Indianapolis, IN), using the Hitachi 
Modular Analytics system (Roche Diagnostics, Mannheim, 
Germany). Non-high density lipoprotein cholesterol (non-
HDL-C) values were obtained by subtracting HDL-C 
from TC values26. LDL-C concentration was calculated 
with the Friedewald formula. TC/HDL-C, LDL-C/HDL-C 
and TG/HDL-C ratios were calculated by dividing TC, 
LDL-C and TG by HDL-C, respectively.
Dyslipidemia was classified according to the National 
Cholesterol Education ProgramAdult Treatment Panel III 
(NCEP-ATP III) guidelines26, which considered the follow-
ing levels elevated: TC ≥200 mg/dL, LDL-C ≥130 mg/dL, 
TG ≥150 mg/dL and non-HDL-C ≥160 mg/dL. HDL-C 
values<50 mg/dL were considered low. Ratios were consid-
ered high when the following values were observed: TC/
HDL-C >4.5, LDL-C/HDL-C >3.0 and TG/HDL-C >4.0.
Cardiovascular risk assessment
The FRS was validated in a cohort of 5,345 US adults 
(2,856 women and 2,489 men), aged between 30 and 
74 years, followed for12 years19. The FRS was developed 
to assess the relative importance of CHD risk factors 
and measure the absolute risk of CHD in each patient. 
The variables used to calculate the FRS were age, gender, 
smoking status, blood pressure levels, diabetes and values 
of TC and HDL-C. The10-year CHD riskis classified as 
low (<10%), moderate (10–20%) and high (>20%)19.
The SCORE project assembled a pool of datasets 
from 12 European cohort studies, including 205,178 
people (88,080 women and 117,098 men), aged between 
45 and 64 years20. The SCORE project estimated the 
total 10-year risk of developing fatal CVD based on age, 
gender, systolic blood pressure, smoking status and TC 
level or TC/HDL-C ratio. There are versions for low- 
and high-risk regions. The 10-year risk of fatal CVD 
is classified as low (<3%), moderate (≥3 and <5%) and 
high (≥5%)20.
Statistical analysis
Results were presented as means and standard 
deviations (SD) or as absolute and relative frequencies, 
according to the type of variable. The prevalence of 
CVD risk factors was calculated. The kappa coefficient 
was used to measure the degree of agreement between 
cardiovascular risk estimated by the Framingham and 
SCORE risk assessment models. The kappa coefficient 
and its respective 95% confidence interval (CI) were 
estimated using SAS software.
Results
The prevalence of overweight, obese and hyper-
tensive patients was 43, 25 and 34%, respectively. 
The overall prevalence of dyslipidemic patients was 
90%. The most common lipid disorders were high TC 
(70%), high LDL-C (51%) and high non-HDL-C (48%). 
The prevalence of high non-HDL-C in BCS with TG 
≥200 mg/dL was 3%. The prevalence of other CVD 
risk factors is shown in Table 2.
Based on the FRS, 22% of BCS had a high10-year risk 
for CHD. According to the SCORE model, 100 and 93% 
of BCS had a low10-year risk of fatal CVD, considering 
populations at low and high risk for CVD, respectively. 
Considering Brazilian BCS as population at low or high 
risk for CVD, none of the participants were classified as 
high risk by the SCORE system (Table 3).
Considering populations at high risk for CVD, 30 BCS 
were classified as having a low 10-year risk of CVD and 
4 BCS were classified as having a moderate 10-year risk 
of CVD by both cardiovascular risk models. Agreement 
between the FRS and SCORE system was poor (kappa: 
0.1; 95%CI 0.01–0.2).
Based on the SCORE system, none of the participants 
had a moderate or high10-year risk of developing fatal 
CVD, considering populations at low risk for this condi-
tion. Thus, a kappa coefficient could not be obtained for 
populations at low risk for CVD.
Table 1. Sociodemographic and clinical characteristics of middle-aged breast cancer survivors
Characteristics n %
Race
White 49 73
Non-white 18 27
Marital status
With partner 47 70
Without partner 20 30
Menopause status
Premenopause 11 16
Postmenopause 56 84
Type of surgery
Mastectomy 36 54
Breast-conserving surgery 31 46
Chemotherapy 48 72
Radiotherapy 48 72
Chemotherapy + Radiotherapy 38 57
Tumor stage
0 8 12
I 11 16
II 37 56
III 11 16
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Discussion
The prevalence of CVD risk factors in our study 
participants was high, with 68% of these women be-
ing overweight or obese, slightly higher than the 56% 
of BCS previously reported to be overweight or obese9. 
Moreover, the prevalence of metabolic syndrome among 
158 postmenopausal Brazilian BCS was found to be 
48.1%27. Abdominal fat was the most frequent diagnos-
tic criterion of metabolic syndrome in BCS, occurring 
in 54.4% of participants27. BCS may gain weight after 
diagnosis and treatment10,27, with each 5 kg weight gain 
associated with a 12% increase in all-cause mortality, 
a 13% increase in breast cancer-specific mortality and a 
19% increase in mortality from CVD10.
Furthermore, obesity may be associated with hy-
pertension. High blood pressure was common in our 
sample, affecting 34% of BCS. In a study of 494 BCS, 
the most common comorbid condition was hypertension, 
with a rate of 19%9. Other studies reported hyperten-
sion in 2614 and 50.6%27 of BCS. In the Shanghai Breast 
Cancer Survival (SBCS) study, hypertension was the most 
 common comorbid condition, affecting 22.4% of the par-
ticipants28. In the Life after Cancer Epidemiology (LACE) 
study, hypertension was independently associated with an 
increased risk of all-cause mortality, due to causes both 
related and unrelated to breast cancer29. This association 
disappeared, however, after adjusting for antihyperten-
sive medication29. The prevalence of hypertension in our 
sample and in other studies is of concern, indicating the 
need to control blood pressure to minimize the deleteri-
ous effects of hypertension.
Another CVD risk factor was diabetes mellitus, re-
ported by 10% of the participants. Similarly, other studies 
have reported diabetes mellitus in 6.228, 811 and 9%14 of 
BCS. In the SBCS study, diabetes was associated with a 
40% higher risk of total mortality and death unrelated to 
breast cancer, but not breast cancer-specific mortality28. 
In another study of BCS, diabetes was associated with 
a 39% increased risk of all-cause mortality, similar to 
rates observed in diabetics without breast cancer30. These 
data indicate an association between diabetes and poorer 
outcomes in breast cancer patients. A worse prognosis in 
BCS may be due to diabetes-related complications, such 
as insulin resistance and/or hyperinsulinemia30.
Dyslipidemia, which may be associated with obesity, 
hypertension and diabetes8,9, was detected in 90% of our 
study participants. The prevalence of dyslipidemia in 
middle-aged women without breast cancer was shown to 
be 71.5% in Chile3 and 63.4% in Iran4. The most common 
lipid disorders were high TC, LDL-C and non-HDL-C 
concentrations. LDL-C is a major cause of CHD, as well 
as the primary target of lipid-lowering therapy26. BMI has 
been found to be related to TC8,9 and LDL-C8 concentra-
tions in BCS, similar to findings in non-BCS6. A study 
of 104 Brazilian postmenopausal BCS found that the 
rates of high TC and high LDL-C were 56.7 and 83.4%, 
respectively31. Moreover, a prospective study of non-BCS 
found that the menopause transition was associated with 
significant increases in TC and TG concentrations6. The 
Study of Women’s Health Across the Nation (SWAN) 
found that TC, LDL-C and TG levels peaked during late 
perimenopause and early postmenopause5. These findings 
may explain, at least in part, the prevalence of dyslipid-
emia in our study cohort and emphasize the importance 
of evaluating lipid profiles in middle-aged BCS.
The numbers of BCS in this study with high 
TC/HDL-C, LDL-C/HDL-C and TG/HDL-C ratios were 
not negligible. LDL-C/HDL-C ratio was shown to in-
crease following menopause32, whereas TG/HDL-C33 and 
TC/HDL-C6,32 ratios were found to increase during the 
menopause transition and postmenopausal periods, two 
phases the BBCAM study participants were going through. 
Considering the predictive capacity of CVD risk ratios, 
our results merit attention in clinical practice, since a 
considerable proportion of women in our study cohort 
BCS had elevated ratios, indicating that these women 
were at higher risk of CVD.
Table 3. Risk of cardiovascular disease in middle-aged breast cancer survivors, according 
to Framingham and Systematic Coronary Risk Evaluation risk assessment models
Cardiovascular risk
Framingham SCOREa SCOREb
n % n % n %
Low 30 45 67 100 62 93
Moderate 22 33 – – 5 7
High 15 22 – – – –
aTen-year risk of fatal cardiovascular disease in populations at low risk for 
cardiovascular disease; bten-year risk of fatal cardiovascular disease in populations 
at high risk for cardiovascular disease.
SCORE: Systematic COronary Risk Evaluation.
Table 2. Prevalence of cardiovascular risk factors in middle-aged breast cancer survivors
Cardiovascular risk factors n %
Obesity 17 25
Hypertension 23 34
Diabetes mellitus 7 10
Smoking status 8 12
Dyslipidemia 60 90
High total cholesterol (≥200 mg/dL) 47 70
High LDL-cholesterol (≥130 mg/dL) 34 51
Low HDL-cholesterol (<50 mg/dL) 27 40
High non-HDL-cholesterol (≥160 mg/dL) 32 48
High triglyceride (≥150 mg/dL) 27 40
High TC/HDL-C ratio (>4.5) 24 36
High LDL-C/HDL-C ratio (>3.0) 19 28
High triglyceride/HDL-C ratio (>4.0) 18 27
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Tobacco smoking, another established CVD risk 
factor, was reported by 12% of the women in our study 
cohort. Tobacco smoke may lead to coronary endothelial 
dysfunction and atherosclerosis, possibly via oxidative 
stress34. Furthermore, cigarette smoking may be associ-
ated with increased mortality in BCS35. For example, 
results from the LACE study showed that current smokers 
were at a twofold increased risk of breast cancer-specific 
mortality and a fourfold higher risk of death unrelated 
to breast cancer35 than never smokers. The mechanism 
relating smoking to poorer outcomes in BCS is not 
completely understood.
The combination of smoking and radiotherapy has 
been found to have a more than additive effect on the risk of 
myocardial infarction14. Radiotherapy was employed to treat 
72% of our participants. Radiation-related heart toxicities 
include diseases of the pericardium and myocardium, coronary 
artery disease, valvular dysfunction and conduction abnor-
malities14,36. A population-based case-control study involving 
2,168 breast cancer patients found that women irradiated 
for cancer in the left breast had significantly higher rates of 
major coronary events (i.e., myocardial infarction, coronary 
revascularization, or death from ischemic heart disease) than 
those irradiated for cancer in the right breast37. Morphology 
was similar in patients with radiation-related CHD and 
spontaneous atherosclerosis36.
Other therapeutic modalities commonly used to 
treat breast cancer patients include chemotherapy, tar-
geted therapy and endocrine therapy. Anthracyclines are 
the most frequently used chemotherapeutic agents for 
breast cancer. Anthracycline cardiotoxicity is related to 
cumulative dose, increasing the risk of cardiomyopathy 
and congestive heart failure13. Chemotherapy-related 
cardiac ischemia is uncommon. However, associations 
between 5-fluorouracil use and myocardial ischemia have 
been reported15. Data on the chemotherapy agents used 
in our patients could not be retrieved. Although the tar-
geted therapy trastuzumab has been associated with an 
increased risk of heart failure16, this agent was not avail-
able to treat BCS at the time this study was performed. 
Endocrine therapy with tamoxifen may reduce TC and 
LDL-C, while increasing TG levels18. A systematic review 
found that the use of aromatase inhibitors, compared 
with tamoxifen, was associated with increased odds of 
developing CVD and hypercholesterolemia17.
BCS have multiple risk factors for CVD, including 
both traditional and treatment-related factors. Despite 
the elevated prevalence of risk factors, none of the partici-
pants was categorized using the SCORE model as being 
at highrisk of CVD, whereas 22% were found to be at 
highrisk according to the FRS model. FRS and SCORE 
models may overestimate or underestimate CVD risk 
in different scenarios21,22. A recent systematic review 
evaluating the use and validity of CVD risk prediction 
models in Latin America and the Caribbean and among 
Hispanic populations in the United States reported that 
FRS overestimates CVD risk among Hispanics when 
not adequately recalibrated22. We found that the agree-
ment between the two risk models was poor. Although 
no previous studies evaluated the FRS and SCORE risk 
models in middle-aged BCS, similar results have been 
reported in other settings23,24. For example, the agreement 
between FRS and SCORE models in poor Spanish middle-
aged women23 and in HIV-positive Brazilian patients24.
This study had several limitations, including its cross-
sectional design and relatively small sample size. To our 
knowledge, this is the first study from Latin America to 
evaluate the agreement between two CVD risk models 
in BCS. Routine follow-up of BCS should include lipid 
profiles and CVD risk assessment.
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